Mycophenolate REMS Program: CE Request for Grant Application

ACCME Newsletter (03/25/21) Vol. 12, No. 13

The U.S. Food and Drug Administration (FDA) has added accredited continuing education (CE) to the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) program. This is the second time the agency has included accredited CE a REMS. The objective is to uphold REMS-compliant, accredited CE for mycophenolate prescribers to enhance patient understanding of risks associated with the drug. The grant application process is open, with applications due by May 14.

Read More

Recent Stories
Alliance Podcast Episode 18: Spotlight on Leadership

Comparison of In-Person Versus Tele-Ultrasound Point-of-Care Ultrasound Training During the COVID-19 Pandemic

Rockpointe Presents Online CME Course on Treating High-Risk Patients With COVID-19